← Back to Clinical Trials
Recruiting Phase 4 NCT05522465

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Trial Parameters

Condition Immune Thrombocytopenia
Sponsor Fujian Medical University Union Hospital
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 608
Sex ALL
Min Age 29 Days
Max Age 14 Years
Start Date 2022-10-11
Completion 2025-08-31
Interventions
PrednisoneDexamethasone

Brief Summary

Comparison of the efficacy and safety of short-course high-dose prednisone and dexamethasone in the treatment of children with newly diagnosed immune thrombocytopenia (ITP)

Eligibility Criteria

Inclusion Criteria:Subjects enrolled in this study must meet all of the following criteria: 1. Meet the ITP diagnostic criteria, within 3 months of the first diagnosis 2. Age \> 28 days and ≤ 14 years old 3. Untreated PLT\<20×109/L, or PLT\<30×109/L after 1 week of intravenous gamma globulin (IVIG) treatment 4. Have signed the informed consent Exclusion Criteria:Anyone who has any of the following conditions will not enter the clinical study: 1. Intracranial hemorrhage or severe gastrointestinal or urinary tract hemorrhage requiring emergency treatment, such as simultaneous use of platelet transfusion and thrombopoietic drugs (recombinant human thrombopoietin, eltrombopag, etc.) 2. Received glucocorticoid therapy within 6 months 3. Menstrual female children 4. Patients with underlying diseases such as tumor diseases, autoimmune diseases or genetic diseases 5. Patients who have received radiotherapy and chemotherapy 6. There are contraindications to the use of glucocorticoids (hypertens

Related Trials